1-7 of 7
Yuying Jin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Clinical Trials & Observations
Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini
Journal: Blood
Blood (2023) 142 (14): 1208–1218.
https://doi.org/10.1182/blood.2022019406
Published: 2023
Includes: Supplemental data
Journal Articles

Survival Benefit of Birtamimab in Mayo Stage IV AL Amyloidosis in the Phase 3 VITAL Study Consistent after Adjustment for Key Baseline Variables

Morie A. Gertz, Yuying Jin, Ansgar Conrad, Christie Nie
Journal: Blood
Blood (2022) 140 (Supplement 1): 1839–1840.
https://doi.org/10.1182/blood-2022-159801
Published: 2022
Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Maro Ohanian, Martha L. Arellano, Moshe Y. Levy, Kristen O'Dwyer, Hani Babiker, Daruka Mahadevan, Hongying Zhang, Nasrin Rastgoo, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar
Journal: Blood
Blood (2021) 138 (Supplement 1): 3411.
https://doi.org/10.1182/blood-2021-150049
Published: 2021
Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul Koller, Jessica K. Altman, Mohamad Cherry, Benjamin Tomlinson, Namrata Chandhok, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Yuying Jin, Genia Su, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar
Journal: Blood
Blood (2021) 138 (Supplement 1): 1272.
https://doi.org/10.1182/blood-2021-149333
Published: 2021
Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Felipe Samaniego, John M. Burke, Daruka Mahadevan, Mohamad Cherry, Ahad A. Sadiq, M. Zach Koontz, Jose C. Villasboas, Erin Reid, Elizabeth Cull, Victor Priego, Lindsey E. Roeker, Patrick Cobb, Jason Melear, Paul Conkling, David Cosgrove, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Donna Nguyen Haney, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar
Journal: Blood
Blood (2021) 138 (Supplement 1): 1355.
https://doi.org/10.1182/blood-2021-148827
Published: 2021
Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-141495
Published: 2020
Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141409
Published: 2020